A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems.
Prohibited in competition. This compound is on the WADA Prohibited List (class [S0 / S2.3 / S2]), banned at all times, both in and out of competition. Athletes subject to WADA or USADA testing should not use it.
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. First described in the scientific literature in the 1990s by Dr. Predrag Sikiric and colleagues at the University of Zagreb, it has since become one of the most extensively studied research peptides, with over 100 published preclinical studies. Its healing properties span an extraordinary range of tissues including tendons, ligaments, muscles, bone, the gastrointestinal tract, peripheral nerves, and the central nervous system. Unlike many peptides that act on a single pathway, BPC-157 appears to be a pleiotropic healing agent that orchestrates multiple repair cascades simultaneously. It has demonstrated efficacy in models of inflammatory bowel disease, ulcers, fistulas, and even systemic organ damage from NSAIDs or alcohol.
1419.53 Da
250–500 mcg
Once or twice daily
“A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems.”
BPC-157 exerts its effects through several interconnected molecular pathways. Its primary mechanism involves activation of the FAK-paxillin signaling pathway, which drives cytoskeletal reorganization and cell migration essential for wound healing. It robustly upregulates growth hormone receptor (GHR) expression in tendon fibroblasts, amplifying the tissue’s sensitivity to endogenous GH signals. BPC-157 also activates the nitric oxide (NO) system, promoting vasodilation and angiogenesis — the formation of new blood vessels that supply oxygen and nutrients to healing tissue. In the gastrointestinal tract, it modulates the expression of VEGF and EGF receptors. Additionally, it interacts with the dopaminergic and serotonergic systems in the brain, which may explain its reported anxiolytic and neuroprotective effects. The peptide also appears to counteract the damaging effects of NSAIDs on the GI mucosa by preserving prostaglandin synthesis.
Subcutaneous injection
For systemic effects, subcutaneous injection near the injury site is preferred. For GI conditions, oral administration may be used.
Lyophilized: room temperature up to 3 months, refrigerated up to 2 years. Reconstituted: refrigerate and use within 30 days.
When sourcing BPC-157 for research purposes, the following quality benchmarks should be verified before use.
>98% (verified by HPLC)
Must be provided by supplier
<0.1 EU/mg (prevents bacterial contamination)
Manufactured in cGMP-certified facility
Independent lab verification preferred
BPC-157 is prohibited by WADA under class S0 (unapproved substances), at all times, both in and out of competition. Any athlete subject to WADA or USADA testing should not use it.
Regulatory status
BPC-157 is not FDA-approved for any use and is not a lawful dietary ingredient. FDA placed it in Category 2 (significant safety risks) for compounding purposes in September 2023. A July 2026 FDA advisory committee voted to recommend several peptides for the 503A bulk-substances list over FDA staff’s objection, but that vote is non-binding and nothing has legally changed.
Unresolved safety questions
– Pro-angiogenic activity via VEGFR2, with unresolved questions about tumour promotion
– Animal signals of altered clotting and liver abnormalities
– Immunogenicity risk flagged by FDA
– No carcinogenicity study has been performed
– No pharmacopeial purity standard exists, so vial-to-vial identity and purity cannot be verified
Lyophilized: room temperature up to 3 months, refrigerated up to 2 years. Reconstituted: refrigerate and use within 30 days.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Early-stage research only. Significant uncertainty about efficacy and safety in humans.
Animal & In-Vitro Only — Mechanism observed in cell culture or animal models. No human efficacy data. Not evidence of an effect in humans.
Peptides commonly used alongside BPC-157 for synergistic effects.
A short-acting GHRH analog that produces physiological GH pulses when combined with a GHRP like Ipamorelin.
The most selective GHRP available, stimulating GH release with minimal cortisol or prolactin elevation.
A synthetic analog of Thymosin Beta-4 that promotes systemic healing through actin regulation and angiogenesis.
Category
Status
Dose
Frequency
Cycle
Peptides
Protocols
Other Pages
Contact Us Today!
© 2026 Best Health IQ. All rights reserved.
FDA Disclaimer: The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many compounds described on this site are not approved by the FDA for human therapeutic use. Some are available only as compounded preparations or as materials sold for laboratory use, and several are on FDA's Category 2 list for significant safety risks. Nothing on this site constitutes medical advice or a recommendation to use any compound described.
